Biomedical Engineering Reference
In-Depth Information
45. Zhou J, Wang X, Pineyro MA, Egan JM (1999) Glucagon-like peptide 1 and exendin-4
convert pancreatic AR42 J cells into glucagon- and insulin-producing cells. Diabetes
48(12):2358-2366
46. Gallwitz B (2011) GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp
Pharmacol 203:53-74
47. Herbach N, Goeke B, Schneider M, Hermanns W, Wolf E, Wanke R (2005) Overexpression
of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal
pancreatic islet and beta-cell development. Regul Pept 125(1-3):103-117
48. Marenah L, McCluskey JT, Abdel-Wahab YH, O'Harte FP, McClenaghan NH, Flatt PR
(2006) A stable analogue of glucose-dependent insulinotropic polypeptide, GIP
(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells
expressing islet-specific genes and hormones. Biol Chem 387(7):941-947
49. Irwin N, Clarke GC, Green BD, Greer B, Harriott P, Gault VA, O'Harte FP, Flatt PR (2006)
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus
mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem
Pharmacol 72(6):719-728
50. Kuntz E, Pinget M, Damge P (2004) Cholecystokinin octapeptide: a potential growth factor
for pancreatic beta cells in diabetic rats. JOP 5(6):464-475
51. Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL, Koltes JE,
Dawson JA, Yandell BS, Samuelson LC, Beinfeld MC, Davis DB, Hellerstein MK, Keller
MP, Attie AD (2010) Cholecystokinin is up-regulated in obese mouse islets and expands
beta-cell mass by increasing beta-cell survival. Endocrinology 151(8):3577-3588
52. Ahren B, Holst JJ, Efendic S (2000) Antidiabetogenic action of cholecystokinin-8 in type 2
diabetes. J Clin Endocrinol Metab 85(3):1043-1048
53. Rooman I, Lardon J, Bouwens L (2002) Gastrin stimulates beta-cell neogenesis and
increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue.
DiabetesDiabetes 51(3):686-690
54. Wang TC, Bonner-Weir S, Oates PS, Chulak M, Simon B, Merlino GT, Schmidt EV, Brand SJ
(1993) Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-
induced ductular precursor cells. J Clin Invest 92(3):1349-1356
55. Rooman I, Bouwens L (2004) Combined gastrin and epidermal growth factor treatment
induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with
alloxan. Diabetologia 47(2):259-265
56. Brand SJ, Tagerud S, Lambert P, Magil SG, Tatarkiewicz K, Doiron K, Yan Y (2002)
Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell
regeneration with systemic co-administration of EGF and gastrin. Pharmacol Toxicol
91(6):414-420
57. Massague J, Chen YG (2000) Controlling TGF-beta signaling. Genes Dev 14(6):627-644
58. Kim SK, Hebrook M, Li E, Oh SP, Schrewe H, Harmon EB, Lee JS, Melton DA (2000)
Activin receptor patterning of foregut organogenesis. Genes Dev 14(15):1866-1871
59. Furukawa M, Eto Y, Kojima I (1995) Expression of immunoreactive activin A in fetal rat
pancreas. Endocr J 42(1):63-68
60. Shiozaki S, Tajima T, Zhang YQ, Furukawa M, Nakazato Y, Kojima I (1999) Impaired
differentiation of endocrine and exocrine cells of the pancreas in transgenic mouse
expressing the truncated type II activin receptor. Biochim Biophys Acta 1450(1):1-11
61. Zhang YQ, Zhang H, Maeshima A, Kurihara H, Miyagawa J, Takeuchi T, Kojima I (2002)
Up-regulation of the expression of activins in the pancreatic duct by reduction of the b cell
mass. Endocrinology 143(9):3540-3547
62. Moriya N, Komazaki S, Takahashi S, Yokota C, Asashima M (2000) In vitro pancreas
formation from Xenopus ectoderm treated with activin and retinoic acid. Dev Growth Differ
42(6):593-602
63. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J (1993)
Betacellulin: a mitogen from pancreatic b-cell tumors. Science 259(5101):1604-1607
